NCT02578121撤回2 期
A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Response rate after combination of Ixazomib, Pomalidomide and Dexamethasone therapy
研究概览
简要总结
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
详细描述
This single arm, Phase II study will examine the efficacy and safety of the novel Proteasome/IMiD combination of Ixazomib 4mg days 1, 8, 15, Pomalidomide 4 mg days 1-21, Dexamethasone 20 mg days 1, 8, 15, and 22 of a 28 day cycle, in relapse patients. The long term aim being to develop a backbone regimen to which future novel targeted treatments may be added as part of a personalized medicine approach.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- •Male or female patients 18 years or older.
- •Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •Female patients who:
- •Are postmenopausal for at least 1 year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- •Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following: Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- •Patients must have a diagnosis of relapsed and/or refractory multiple myeloma and must have received at least one line of prior therapy. Patients must be at least 14 days beyond the last multiple myeloma therapy and have recovered from acute toxicities of prior therapies measured by CTCAE (Version 4.0)
- •Patients must have life expectancy of at least 3 months.
- •Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or
- •Patients must meet the following clinical laboratory criteria:
- •Absolute neutrophil count (ANC) > 1,000/mm3 and platelet count> 50,000/mm
- •Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment. Total bilirubin <1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN. Calculated creatinine clearance > 30 mL/min (see APPENDIX C for the Cockcroft-Gault Equation).,
排除标准
- •Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
- •Female patients who are lactating or have a positive serum pregnancy test during the screening period.
- •Failure to have fully recovered (ie, < Grade 1 toxicity) from the reversible effects of prior chemotherapy.
- •Major surgery within 14 days before enrollment.
- •Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days will be considered a sufficient interval.
- •Central nervous system involvement.
- •Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
- •Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
- •Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive.
- •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
- •Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
- •Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of oral medications including difficulty swallowing.
- •Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
- •Patient has > Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical examination during the screening period.
- •Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial.
研究组 & 干预措施
Ixazomib, Pomalidomide, Dexamethasone
Experimental
Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
干预措施: Ixazomib (Drug)
Ixazomib, Pomalidomide, Dexamethasone
Experimental
Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
干预措施: Pomalidomide (Drug)
Ixazomib, Pomalidomide, Dexamethasone
Experimental
Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Response rate after combination of Ixazomib, Pomalidomide and Dexamethasone therapy
时间窗: 28 days
Response rate will be assessed at baseline, with each scheduled study visit , including the exit visit.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT03202628Mayo Clinic8
招募中
4 期
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaMultiple MyelomaNCT05722405Second Affiliated Hospital, School of Medicine, Zhejiang University100
已完成
2 期
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaPlasma Cell MyelomaPlasma Cell LeukemiaPlasmacytomaNCT02547662Mayo Clinic17
已完成
2 期
Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.Multiple MyelomaNCT02461888University of Leeds112
进行中（未招募）
1 期
Ixazomib + Pomalidomide + Dexamethasone In MMMultiple Myeloma in RelapseMultiple MyelomaNCT04094961Omar Nadeem, MD52